

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 5, 2006

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)

Delaware 0-26224 51-0317849
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification No.)

311 Enterprise Drive
Plainsboro, NJ 08536
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (609) 275-0500

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

- Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On March 5, 2006, Integra LifeSciences Holdings Corporation issued a press
release announcing financial results for the quarter and year ended December 31,
2005. A copy of the press release is attached as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated by reference into this Item.

The information contained in Item 2.02 of this Current Report on Form 8-K
(including the press release) is being furnished and shall not be deemed "filed"
for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or otherwise subject to the liabilities of that
Section. The information contained in Item 2.02 of this Current Report on Form
8-K (including the press release) shall not be incorporated by reference into
any registration statement or other document pursuant to the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by
specific reference in any such filing.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

Exhibit Number Description of Exhibit

99.1 Press release issued March 5, 2006 regarding earnings for the
quarter and year ended December 31, 2005

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: March 6, 2006

By: /s/ Stuart M. Essig

Stuart M. Essig
President and Chief Executive Officer

Exhibit Index

Exhibit Number Description of Exhibit

99.1 Press release issued March 5, 2006 regarding earnings for the
 quarter and year ended December 31, 2005

Contacts:

Integra LifeSciences Holdings Corporation

David B. Holtz
Senior Vice President, Finance
(609) 936-2334
dholtz@Integra-LS.com

Maria Platsis
Senior Director of Investor Relations
and Corporate Development
(609) 936-2333
mplatsis@Integra-LS.com

Integra LifeSciences Reports Record Revenues
for the Fourth Quarter and Full Year 2005

Plainsboro, New Jersey, March 5, 2006 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its fourth quarter and full year 2005 revenues and earnings. Total revenues in the fourth quarter of 2005 were \$73.0 million, reflecting an increase of \$11.2 million, or 18%, over the fourth quarter of 2004. Total revenues for the full year ended December 31, 2005 increased by \$48.1 million to \$277.9 million, a 21% increase over the prior year.

We reported net income of \$10.6 million, or \$0.33 per diluted share, for the fourth quarter of 2005, compared to net income of \$9.8 million, or \$0.30 per diluted share in the fourth quarter of 2004. Net income for the year ended December 31, 2005 was \$37.2 million, or \$1.15 per diluted share, compared to \$17.2 million, or \$0.55 per diluted share for the year ended December 31, 2004.

When adjusted for certain restructuring related charges, net income for the fourth quarter of 2005 was \$12.1 million, or \$0.37 per diluted share, and net income for the full year 2005 was \$42.1 million, or \$1.29 per share. During the fourth quarter, these charges included costs associated with the closing of various facilities and related transitions, employee terminations, and other integration and restructuring related costs. In 2004, net income, when adjusted for certain charges set forth in the tables at the end of this release, was \$9.9 million, or \$0.30 per diluted share, in the fourth quarter, and \$33.6 million, or \$1.03 per share, for the full year.

Both our reported net income and our adjusted net income benefited from a reduction in our effective income tax rate, which decreased to 32.5% for the full year. This decline was primarily related to our ability to recognize net operating losses in a foreign jurisdiction due to the settlement of an income tax audit, tax credits that became recognizable in the fourth quarter and changes in the geographical mix of our pre-tax income.

"I am pleased with our performance in the fourth quarter and for the year," said Stuart M. Essig, Integra's President and Chief Executive Officer. "During the year, we achieved record revenues. We also completed the acquisition of the Newdeal companies and added their international business to our existing sales and distribution network. We substantially increased the headcount in both our European sales and marketing departments and our domestic Reconstructive Surgery sales force, and we launched several exciting new products for the treatment of wounds and the surgical reconstruction of the foot and ankle.

"During the third quarter, we agreed to acquire the assets of the Radionics Division of Tyco Healthcare Group LP. The transaction, which closed on March 3, 2006, represents an ideal strategic fit for Integra. We expect the Radionics

acquisition to increase our revenues in 2006 by approximately 12 percent, enhance our cash flow and profitability, and increase the proportion of our business that comes from outside the United States.

"In 2005, we also accelerated product development, having launched new products in dural regeneration, adhesion prevention, nerve repair, cranial reconstruction and shunting for normal pressure hydrocephalus. Finally, we continued to cut costs and improve margins through plant consolidations, closing manufacturing sites in Texas and Germany, and restructuring our French manufacturing facility."

Our revenues for the period were as follows:

	Three Months		Year	
	Ended December 31, 2005	2004	Ended December 31, 2005	2004
	----	----	----	----
Revenue:	(\$ in thousands)			
Implants	\$28,370	\$10,851	\$108,156	\$78,418
Instruments	24,008	22,685	91,918	77,667
Monitoring	13,032	12,517	48,940	48,217
Private label & other	7,566	6,758	28,921	25,523
Total Revenue	\$72,985	\$61,811	\$277,935	\$229,825

~~Sales of our Reconstructive Surgery implant products grew particularly well. Rapid growth in the NeuraGen(TM) Nerve Guide, the INTEGRA(TM) dermal repair~~

~~products and sales of Newdeal products for the foot and ankle accounted for most of the increase in implant product revenues. INTEGRA(TM) dermal repair product revenues increased approximately 86% over the fourth quarter of 2004, nerve repair product revenues increased by 55%, and our Newdeal foot and ankle products achieved record revenues of \$4.8 million in the quarter. Our DuraGen(R) family of duraplasty products continued to grow, although at slower rates than in recent years. Sales of the DuraGen Plus(TM) and Suturable DuraGen(TM) Dural Regeneration products led the growth in sales of this group of products. Sales of the NPH(TM) Low Flow Hydrocephalus Valve also contributed to the growth in implant product revenues for the quarter.~~

~~Monitoring revenues grew at 4% over the fourth quarter of 2004, an improvement over the last several quarters. Increased sales of our intracranial monitoring products, drainage systems, and cranial access kits accounted for the increase in monitoring product revenues. Sales of our LICOX(R) Brain Oxygen Monitoring System product line increased approximately 39% over the prior year period. We have developed a new targeted account sales and marketing strategy for products in this category, and we expect that it will contribute to improvements in the performance of our monitoring products in future periods.~~

~~Increased revenues of the Absorbable Collagen Sponge that we supply for use in Medtronic's INFUSE(TM) bone graft product led the growth in revenues of our private label products. In the fourth quarter of 2005, we recognized an additional \$1.3 million of royalty revenue related to a change in the manner we use to estimate royalties based on Medtronic's sales of its INFUSE(TM) bone graft product.~~

~~Excluding recently acquired product lines and changes in foreign currency exchange rates, fourth quarter 2005 revenues increased by \$7.2 million, or 12%, over the prior year period. Changes in foreign currency exchange rates had a negative impact of \$0.9 million on our quarterly year over year revenue growth.~~

~~Gross margin on total revenues in the fourth quarter of 2005 was 61%. Although we had strong growth in higher gross margin products, we incurred approximately \$1.3 million in restructuring and manufacturing transfer costs. These charges reduced our gross margin by approximately 2%.~~

Research and development expense decreased from \$3.6 million in the fourth quarter of 2004 to \$2.7 million in the current period.

Selling, general and administrative expense increased by \$5.4 million to \$25.7 million in the fourth quarter of 2005, increasing as a percentage of revenue to 35% from 33% in the prior year period. This increase was primarily attributable to expenses of acquired operations, as well as the further development of our European infrastructure. The increase included approximately \$752,000 of charges associated with the closing of various facilities and related transitions, employee terminations and other acquisition, integration and restructuring related costs. These charges increased selling, general and administrative expense by 1% of revenues.

We reported net interest income of \$16,000 in the fourth quarter of 2005 compared to \$95,000 in the prior year period.

The Company generated \$15.1 million in cash flows from operations in the fourth quarter of 2005. We repurchased 900,000 shares of our common stock in the quarter at an average price of \$25.21 per share for an aggregate purchase price of approximately \$31.7 million. Our cash and investments totaled \$143 million at December 31, 2005.

In December 2005, we established a \$200 million, five year, senior secured revolving credit facility. This new line of credit provides us with increased financial flexibility and access to capital to support the Company's continued growth. The credit facility currently allows for revolving credit borrowings in a principal amount of up to \$200 million, which can be increased to \$250 million should additional financing be required in the future. We plan to utilize the credit facility for working capital, capital expenditures, share repurchases, acquisitions and other general corporate purposes.

We are updating our expectations for total revenues, gross margin and earnings per share for 2006 and providing our initial guidance for 2007. Our expectations for 2006 and 2007 financial performance include the impact of the just closed Radionics acquisition, but, in accordance with our usual practice, do not include the impact of acquisitions or other strategic corporate transactions that have not yet closed.

We expect total revenues in 2006 to be between \$365 million and \$380 million, and total revenues in 2007 to be between \$420 million and \$440 million. We expect consolidated gross margin to increase to 65% and 66% of total revenues in 2006 and 2007, respectively, including the impact of purchase accounting related to the Radionics acquisition and share based compensation costs.

We expect that unfavorable foreign currency exchange rate movements will have a negative impact on our revenue growth rates in 2006. If foreign currency exchange rates hold at current levels, our forward looking guidance anticipates an unfavorable impact on net sales of approximately 2% in the first quarter of 2006 and an unfavorable impact on net sales of approximately 1% for the full year of 2006.

Our guidance includes both the direct impact of the Radionics acquisition and our assumption that our sales force will, in some situations, sell the CUSA Excel(TM) ultrasonic aspiration system in lieu of our existing ultrasonic aspirator products.

The Company may incur significant costs this year in connection with restructuring and integration activities, including purchase accounting charges related to the Radionics acquisition. We currently expect these charges to be approximately \$2.5 million in 2006.

The Company also expects the impact of estimated share based compensation expense for 2006 and 2007 to be in the range of \$0.27 to \$0.29 per diluted share.

~~Earnings per diluted share are expected to be within a range of \$1.69 to \$1.76 in 2006, excluding restructuring and integration charges and the impact of estimated share based compensation expense. Earnings per diluted share are expected to be within a range of \$1.95 to \$2.10 in 2007, excluding the impact of estimated share based compensation expense. On a GAAP reported basis, we expect earnings per diluted share to be within a range of \$1.35 to \$1.44 in 2006 and within a range of \$1.66 to \$1.83 in 2007.~~

~~Our guidance for the first quarter of 2006 is for total revenues in the range of \$79 million to \$82 million including a contribution of approximately \$4 million from the Radionics acquisition, and adjusted earnings per diluted share of \$0.34 to \$0.36, excluding restructuring and integration charges of \$0.02 and the impact of estimated share based compensation expense of \$0.07. On a GAAP reported basis, we expect earnings per diluted share to be within a range of \$0.25 to \$0.27 in the first quarter of 2006.~~

~~Our Board of Directors has authorized us to repurchase shares of our common stock for an aggregate purchase price not to exceed \$50 million through December 31, 2006. We may repurchase shares under this program either in the open market or in privately negotiated transactions.~~

~~We have scheduled a conference call for 9:00 am EST tomorrow, March 6, 2006, to discuss the financial results for the fourth quarter of 2005 and forward looking financial guidance. The call is open to all listeners and will be followed by a question and answer session. Access to the live call is available by dialing (913) 312-1295 or through a listen only webcast via a link provided on the home page of Integra's website at www.Integra-LS.com. A replay of the conference call will be accessible starting one hour following the live event. Access to the replay is available through March 20, 2006 by dialing (719) 457-0820 (access code 3248191) or through the webcast accessible on our home page.~~

~~Integra LifeSciences Holdings Corporation is a diversified medical technology company. We develop, manufacture, and market medical devices for use in neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey. We have 1,400 employees located in our research, manufacturing and distribution facilities throughout the world. Please visit our website at (<http://www.Integra-LS.com>).~~

~~This news release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include, but are not limited to, statements concerning future financial performance, including projections for revenues, gross margins, earnings per share and cash flows. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, our ability to maintain relationships with customers of acquired entities, physicians' willingness to adopt our recently launched and planned products and our ability to secure regulatory approval for products in development may adversely affect our future product revenues; our ability to increase sales and product volumes may adversely affect our future gross margins; our ability to integrate acquired businesses (including the Radionics business), increase product sales and gross margins, and control non-product costs may affect our earnings per share; our future net income results and our ability to effectively manage working capital may affect our future cash flows; and our ability to complete the restructuring and integration activities may affect our operating income. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2004 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.~~

~~Regulation G, "Conditions for Use of Non-GAAP Financial Measures," and other provisions of the Securities Exchange Act of 1934, as amended, define and prescribe the conditions for the use of certain non-GAAP financial information.~~

~~In this news release, we provide "adjusted net income" and "adjusted earnings per share", which exclude charges related to acquisitions, integrations and restructurings, and "growth in revenues excluding recently acquired product lines and changes in foreign currency exchange rates", all of which are non-GAAP financial measures. We believe that, given our on going, active strategy of seeking acquisitions and our current focus on rationalizing our existing manufacturing and distribution infrastructure, and the extent of changes in foreign currency exchange rates, net income and earnings per share adjusted to exclude costs related to acquisitions, integrations and restructurings, and growth in revenues excluding recently acquired product lines and changes in foreign currency exchange rates, are useful additional bases to measure the performance of our business operations, both in this quarter and in future periods. In addition, excluding future share based compensation charges from our projected adjusted earnings per share allows for comparability of our guidance to historical periods. A reconciliation of these non-GAAP financial measures to the most comparable GAAP measures is provided in the tables of financial information contained at the end of this news release.~~

~~Non-GAAP financial measures should not be relied upon to the exclusion of GAAP financial measures. Management believes that these non-GAAP financial measures are important supplemental information to investors which reflect an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the accompanying reconciliations, provides a more complete understanding of factors and trends affecting our ongoing business and operations. Management strongly encourages investors to review our financial statements and filed reports in their entirety and to not rely on any single financial measure. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names.~~

~~INTEGRA LIFESCIENCES HOLDINGS CORPORATION~~
~~CONSOLIDATED FINANCIAL RESULTS~~
(In thousands, except per share data)
(UNAUDITED)

~~Statement of Operations Data:~~

	Three Months Ended		December 31, 2004
	Three Months Ended December 31, 2005		December 31, 2004
	Reported	Adjustments	As Adjusted
	Reported	As Adjusted	Reported
Total revenues	\$72,985		\$72,985
Cost of revenues	28,252	\$1,295 (a)	26,957
Research and development	2,704	100 (b)	2,604
Selling, general and administrative	25,663	752 (b)	24,911
Amortization	1,452		1,452
Total costs and expenses	58,071		55,924
Operating income	14,914		17,061
Interest income, net	16		16
Other income (expense), net	(101)		(101)
Income before income taxes	14,829		16,976
Provision for income taxes	4,214	711 (c)	4,925
Net income (loss)	\$10,615		\$12,051
Earnings per share calculation:			
Add back of after tax interest expense	608		608
Net income (loss) for diluted EPS	\$11,223		\$12,659
Diluted earnings (loss) per share	\$0.33		\$0.37
Diluted weighted average common shares outstanding	34,081		34,842

~~Notes:~~

- ~~(a) Costs associated with the closing of various manufacturing facilities and related employee terminations and manufacturing transfers~~
~~(b) Costs associated with the closing of various manufacturing facilities and related employee terminations~~
~~(c) Adjustment to provision for income taxes for above adjustments~~

~~INTEGRA LIFESCIENCES HOLDINGS CORPORATION~~
~~CONSOLIDATED FINANCIAL RESULTS~~
(In thousands, except per share data)
(UNAUDITED)

Statement of Operations Data:

	Twelve Months Ended		December 31, 2004	
	Twelve Months Ended December 31, 2005		December 31, 2004	
	Reported	Adjustments	As Adjusted	Reported
Total revenues	\$277,935		\$277,935	\$229,825
Cost of revenues	105,536	\$4,214	(a)	101,322
Research and development	11,960	735	(b)	11,225
Selling, general and administrative	98,273	2,480	(c)	95,793
Amortization	6,061	216	(d)	5,845
Total costs and expenses	221,830		214,185	205,045
Operating income	56,105		63,750	24,780
Interest income (expense), net	(265)		(265)	555
Other income (expense), net	(739)		(739)	2,674
Income before income taxes	55,101		62,746	28,009
Provision for income taxes	17,907	2,715	(e)	20,622
Net income	\$37,194		\$42,124	\$17,198
Earnings per share calculation:				
Add back of after tax interest expense	2,440		2,440	
Net income for diluted EPS	\$39,634		\$44,564	\$17,198
Diluted earnings per share	\$1.15		\$1.29	\$0.55
Diluted weighted average common shares outstanding	34,565		34,565	31,102

Notes:

- (a) Inventory fair value purchase accounting adjustments, discontinued product lines, costs associated with the closing of various manufacturing facilities, employee terminations, and manufacturing transfers
(b) In process research and development charge and facility closings and related employee terminations
(c) Acquisition and integration related costs, including costs associated with the closing of various facilities, foreign dealer terminations, and employee terminations
(d) Amortization for discontinued product lines
(e) Adjustment to provision for income taxes for above adjustments

Condensed Balance Sheet Data:

	December 31, 2005	December 31, 2004
Cash and marketable securities, including non current portion	\$143,384	\$105,982
Accounts receivable, net	49,007	46,765
Inventory, net	67,476	55,947
Total assets	448,432	456,713
Current liabilities	31,287	24,234
Long term debt	118,378	118,900
Total liabilities	159,614	148,890
Stockholders' equity	289,818	307,823

Reconciliation of non GAAP financial measures to the most comparable GAAP measure:

A. Reconciliation of Net Income and Adjusted Net Earnings

	Quarter Ended		Year Ended	
	December 31,		December 31,	
	2005	2004	2005	2004
(\$ in thousands)				
Net Income	\$ 10,615	\$ 9,830	\$ 37,194	\$17,198
Employee termination costs	1,120		3,861	
Equity based compensation charge				23,876
Inventory fair value adjustments		67	466	270
Facility consolidation, acquisition integration, manufacturing transfer, system integration, and related costs	1,027		2,340	
In process R&D charge and technology licensee fee			500	1,855
Discontinued product lines			478	
Tax effect on above adjustments	(710)	(26)	(2,715)	(10,893)
Tax charge incurred in connection with the reorganization of certain European operations				1,300
Adjusted Net Income	\$ 12,052	\$ 9,880	\$ 42,124	\$33,606
Earnings per share calculation:				
Add back of after tax interest expense	608	598	2,440	2,066
Adjusted Net Income for diluted EPS	\$ 12,660	\$10,478	\$ 44,564	\$35,672
Adjusted Diluted earnings per share	\$0.37	\$0.30	\$1.29	\$1.03
Diluted weighted average common shares outstanding	34,081	34,842	34,565	34,616
Shares added for contingently convertible debt and impact of dilutive stock options				
Diluted weighted average common shares outstanding For Adjusted Diluted earnings per share calculation	34,081	34,842	35,565	34,616

The calculation of diluted earnings (loss) per share for the above periods is presented in the tables above.

B. ~~Growth in product revenues excluding recently acquired product lines and changes in foreign currency exchange rates~~

	Quarter Ended		Increase	
	December 31,		(Decrease)	
	2005	2004	\$	%
(\$ in thousands)				
Total revenues, as reported	\$ 72,985	\$ 61,811	\$11,174	18%
Less: Revenues of product lines acquired since the beginning of the fourth quarter of 2004	4,808		4,808	N/M
Plus: Impact of changes in foreign currency exchange rates	854		854	N/M
Revenues excluding recently acquired product lines and changes in foreign currency exchange rates	\$ 69,031	\$ 61,811	\$ 7,220	12%

D. ~~Reconciliation of Projected Diluted EPS and Projected Adjusted Diluted EPS~~

	Range	
	Low	High
Projected three months ended March 31, 2006:		
Diluted EPS	\$0.25	\$0.27
Facility consolidation and acquisition integration and related costs, including inventory fair value adjustments, net of tax	0.02	0.02
Share based compensation expense, net of tax	0.07	0.07
Adjusted Diluted EPS	\$0.34	\$0.36

	Range	
	Low	High
Projected year ended December 31, 2006:		
Diluted EPS	\$1.35	\$1.44
Inventory fair value adjustments, net of tax	0.02	0.02
Facility consolidation and acquisition integration and related costs, net of tax	0.03	0.03
Share based compensation expense, net of tax	0.29	0.27
Adjusted Diluted EPS	\$1.69	\$1.76

	Range	
	Low	High
Projected year ended December 31, 2007:		
Diluted EPS	\$1.66	\$1.83
Share based compensation expense, net of tax	0.29	0.27
Adjusted Diluted EPS	\$1.95	\$2.10

Source: Integra LifeSciences Holdings Corporation